TAS-116 (Pimitespib)

Catalog No.S7716 Batch:S771601

Technical Data

Formula

C₂₅H₂₆N₈O

Molecular Weight

454.53

CAS No.

1260533-36-5

Solubility (25°C)*

In vitro

DMSO

91 mg/mL (200.2 mM)

Ethanol

11 mg/mL (24.2 mM)

Water

Insoluble

In Vivo (Add solvents to the product individually and in order.)

Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Clear solution	5%DMSO 1 40%PEG300 2 5%Tween80 3 50%ddH2O Validated by Selleck labs. Should you need adjustments to this formulation, contact our sales team for custom testing.	5.000mg/ml (11.00mM)	Taking the 1 mL working solution as an example, add 50 μL of 100 mg/ml clarified DMSO stock solution to 400 μL of PEG300, mix evenly to clarify it; add 50 μL of Tween80 to the above system, mix evenly to clarify; then continue to add 500 μL of ddH2O to adjust the volume to 1 mL. The mixed solution should be used immediately for optimal results.
Clear solution	5% DMSO 1 95% Corn oil Validated by Selleck labs. Should you need adjustments to this formulation, contact our sales team for custom testing.	0.600mg/ml (1.32mM)	Taking the 1 mL working solution as an example, add 50 μL of 12 mg/ml clear DMSO stock solution to 950 μL of corn oil and mix evenly. The mixed solution should be used immediately for optimal results.

* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
* Room temperature shipping (Stability testing shows this product can be shipped without any cooling measures.)

Preparing Stock Solutions

Biological Activity

Description

Pimitespib (TAS-116) is a novel, small-molecule HSP90 inhibitor which inhibits geldanamycin-FITC binding to HSP90 proteins with Ki values of 34.7 nmol/L, 21.3 nmol/L, >50,000 nmol/L, and >50,000 nmol/L for HSP90α, HSP90β, GRP94, and TRAP1, respectively. Furthermore, TAS-116 does not inhibit other ATPases such as HSP70 (IC50 >200 μmol/L).

Targets

HSP90β (Cell-free assay)	HSP90α (Cell-free assay )
21.3 nM(Ki)	34.7 nM(Ki)

In vitro

Pimitespib (TAS-116) is a selective inhibitor of cytosolic HSP90α and β that does not inhibit HSP90 paralogs such as endoplasmic reticulum GRP94 or mitochondrial TRAP1. Treatment of HCT116 cells with 0.3 μmol/L of this compound for 8 hours results in reduced levels of DDR1, which interacts with HSP90α and induction of HSP70, which is a surrogate marker of cytosolic HSP90 inhibition.

In Vivo

Oral administration of Pimitespib (TAS-116) leads to tumour shrinkage in human tumour xenograft mouse models accompanied by depletion of multiple HSP90 clients. In a rat model, the anti-tumour activity of this compound is accompanied by a higher distribution in subcutaneously xenografted NCI-H1975 non-small cell lung carcinoma tumours than in retina. It shows activity against orthotopically transplanted NCI-H1975 lung tumours. Pharmacokinetic profiling in rodent and non-rodent species shows that TAS-116 is orally absorbed and had a bioavailability of almost 100% in mice, 69.0% in rats, and 73.9% in dogs without special formulation. In a HER2-expressing NCI-N87 human gastric cancer xenograft mouse model, chronic administration is tolerable, with the average weight loss in mice not exceeding 10% during the treatment period.

Protocol (from reference)

Cell Assay:^{^[1]}	Cell Lines HCT116 cells Concentrations 0.3, 1 and 3 μM Incubation Time 8 hours Method HCT116 cells are treated with Pimitespib (TAS-116) or 17-AAG for 8 hours. Western blotting is performed by using 10 μg of cell lysate.
Animal Study:^{^[1]}	Animal Models Six-week-old male BALB/c nude mice subcutaneously implanted with cancer cells Dosages 3.6 to 14.0 mg/kg/day Administration oral

References

https://pubmed.ncbi.nlm.nih.gov/25416789/

Sellecks TAS-116 (Pimitespib) Has Been Cited by 6 Publications

Strong Hsp90α/β Protein Expression in Advanced Primary CRC Indicates Short Survival and Predicts Response to the Hsp90α/β-Specific Inhibitor Pimitespib [ Cells, 2025, 14(11)836]	PubMed: 40498011
Heat shock protein 90 chaperone activity is required for hepatitis A virus replication [ J Virol, 2025, e0050225]	PubMed: 40470959
Heat shock protein 90 chaperone activity is required for hepatitis A virus replication [ J Virol, 2025, 99(7):e0050225]	PubMed: 40470959
Targeting HSP90 with Ganetespib to Induce CDK1 Degradation and Promote Cell Death in Hepatoblastoma [ Cancers (Basel), 2025, 17(8)1341]	PubMed: 40282517
Syringaresinol inhibits cardiorenal fibrosis through HSP90 in a cardiorenal syndrome type 2 [ Hum Exp Toxicol, 2023, 42:9603271231165678]	PubMed: 36960691
Single-cell dissection of the multiomic landscape of high-grade serous ovarian cancer [ Cancer Res, 2022, CAN-21-3819]	PubMed: 35969151

RETURN POLICY
Selleck Chemical’s Unconditional Return Policy ensures a smooth online shopping experience for our customers. If you are in any way unsatisfied with your purchase, you may return any item(s) within 7 days of receiving it. In the event of product quality issues, either protocol related or product related problems, you may return any item(s) within 365 days from the original purchase date. Please follow the instructions below when returning products.

SHIPPING AND STORAGE
Selleck products are transported at room temperature. If you receive the product at room temperature, please rest assured, the Selleck Quality Inspection Department has conducted experiments to verify that the normal temperature placement of one month will not affect the biological activity of powder products. After collecting, please store the product according to the requirements described in the datasheet. Most Selleck products are stable under the recommended conditions.

NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.